Related Experiment Video
Updated: Aug 11, 2026

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
Observations on the physostigmine syndrome in patients with Alzheimer's disease
E Wirkowski1, I Prohovnik, W L Young
1Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Abstract:
The authors present two patients with Alzheimer's disease who each received a single intravenous dose of physostigmine. Subjective complaints and mood changes were disproportional with objectively verified physiological side effects. Such observations may contribute to an understanding of affective disorders and should receive more attention in future studies of cholinesterase inhibitors.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer Disease ll: Pathophysiology
Alterations in Muscle Tone lll

